Genentech announced results from the positive Phase III IMmotion151 study of Tecentriq (atezolizumab) and Avastin (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma.
The DUO study showed statistically significant PFS improvement for duvelisib versus standard of care treatment ofatumumab.
